Comparative Pharmacology
Head-to-head clinical analysis: APOGEN versus DENDRID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APOGEN versus DENDRID.
APOGEN vs DENDRID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apocynin is a prodrug that is activated by peroxidases to form dimers that inhibit NADPH oxidase (NOX) enzyme complexes, reducing superoxide production. It also exhibits antioxidant and anti-inflammatory properties.
Dendrid (idoxuridine) is a pyrimidine nucleoside analog that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase, thereby blocking DNA synthesis.
10 mg orally once daily, with or without food.
1.5 mg/kg IV every 8 hours; typical adult dose 100 mg IV every 8 hours.
None Documented
None Documented
Terminal half-life 3.5 hours; dose adjustment required in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged in renal impairment
Renal: 90% unchanged; fecal: 10% as metabolites.
Primarily renal excretion; unchanged drug accounts for 70-90% of elimination; minor biliary/fecal excretion (<10%)
Category C
Category C
Antiviral
Antiviral